Shares of Yum! Brands Inc. (NYSE: YUM) were up over 1% on Monday. The stock has gained 4% over the past three months. The company is scheduled to report its fourth quarter 2022 earnings results on Wednesday, February 8, before market open. Here’s a look at what to expect from the report:
Revenue
Analysts are estimating revenues of $1.92 billion for Yum in Q4 2022, which compares to $1.89 billion reported in Q4 2021. In the third quarter of 2022, revenues increased 2% year-over-year to $1.64 billion.
Earnings
Analysts project EPS of $1.26 for the fourth quarter of 2022 which compares to adjusted EPS of $1.02 in the year-ago quarter. In Q3 2022, adjusted EPS was $1.09, down 11% YoY.

Points to note
In the third quarter of 2022, Yum reported a 5% growth in same-store sales along with unit growth of 6% and system sales growth of 10%. The company opened 979 gross units across 74 countries during the quarter further broadening its vast footprint.
The company’s KFC and Taco Bell divisions saw sales growth in the single digits while Pizza Hut reported a 4% decline during the third quarter. Same-store sales in the KFC division rose 7%, with particular strength in regions like India and the Middle East which benefited from strength across digital channels. The growth in system sales and units during the quarter amid macro headwinds indicates the resilience of this business in a challenging environment.
The Taco Bell division benefited from menu innovation that drove single digit growth in same-store sales and system sales during the third quarter. Yum is benefiting from international expansion with all its units seeing momentum and growth in international markets. Within the US, Yum continues its development despite the challenging environment reflecting the strength of its business.
Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!
Most Popular
TC BioPharm develops safer, less expensive products to target more cancers: CEO Bryan Kobel
TC BioPharm (NASDAQ: TCBP) is a clinical-stage cell therapy company focused on the development of treatments for infectious diseases, including advanced allogeneic chimeric antigen receptor (CAR) T-cell therapy products for
Cintas Corp. (CTAS) Q3 2023 earnings and revenue increase
Uniform rental company Cintas Corporation (NASDAQ: CTAS) on Wednesday announced financial results for the third quarter of 2023, reporting higher earnings and revenues. At $2.19 billion, third-quarter revenues were up
Infographic: Micron (MU) reports net loss for Q2; revenue down 53%
Micron Technology Inc. (NASDAQ: MU) slipped to a loss in the second quarter of 2023 from a profit last year, hurt by a sharp fall in revenues. The chipmaker reported